AKYNZEO Drug Patent Profile

Which patents cover Akynzeo, and when can generic versions of Akynzeo launch?

Akynzeo is a drug marketed by Helsinn Hlthcare and is included in two NDAs. There are twenty-two patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-two patent family members in fifty-three countries.

The generic ingredient in AKYNZEO is fosnetupitant chloride hydrochloride; palonosetron hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the fosnetupitant chloride hydrochloride; palonosetron hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Akynzeo

Akynzeo was eligible for patent challenges on April 19, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 25, 2035. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for AKYNZEO

International Patents:	192
US Patents:	22
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AKYNZEO

Paragraph IV (Patent) Challenges for AKYNZEO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AKYNZEO	Solution in SDV	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	235 mg/0.25 mg per 20 mL	210493	1	2022-04-19

US Patents and Regulatory Information for AKYNZEO

AKYNZEO is protected by twenty-four US patents.

This potential generic entry date is based on patent 9,951,016.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	SOLUTION;INTRAVENOUS	210493-002	May 27, 2020		RX	Yes	Yes	9,908,907		Y	Y
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	SOLUTION;INTRAVENOUS	210493-002	May 27, 2020		RX	Yes	Yes	10,208,073
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	SOLUTION;INTRAVENOUS	210493-002	May 27, 2020		RX	Yes	Yes	8,426,450		Y	Y

International Patents for AKYNZEO

When does loss-of-exclusivity occur for AKYNZEO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Moldova, Republic of

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AKYNZEO around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2494015
Croatia	P20200196
Croatia	P20161708

Supplementary Protection Certificates for AKYNZEO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1035115	C01035115/01	Switzerland		PRODUCT NAME: NETUPITANT; REGISTRATION NO/DATE: SWISSMEDIC 65499 06.11.2015
2785706	LUC00158	Luxembourg		PRODUCT NAME: AKYNZEO - FOSNETUPITANT/PALONOSETRON; AUTHORISATION NUMBER AND DATE: EU/1/15/1001 20200318
1035115	1590040-0	Sweden		PRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150529

AKYNZEO: Intellectual Property and Market Landscape Analysis

Last updated: February 19, 2026

AKYNZEO, comprising netupitant and palonosetron, is a fixed-dose combination drug developed by Eisai and Helsinn for the prevention of chemotherapy-induced nausea and vomiting (CINV). The drug's intellectual property portfolio, coupled with its established market presence and competitive positioning, forms the core of its investment fundamentals. This analysis examines the patent landscape, regulatory approvals, clinical efficacy, market share, and competitive threats to AKYNZEO.

What is the Patent Status of AKYNZEO?

The intellectual property surrounding AKYNZEO is multifaceted, encompassing patents for the specific combination, its individual components, manufacturing processes, and methods of use. The primary patent protection for AKYNZEO in major markets has either expired or is nearing expiration, necessitating an assessment of the remaining market exclusivity and the potential for generic competition.

Netupitant, a selective NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist, are the active pharmaceutical ingredients in AKYNZEO. Patents covering palonosetron (under the brand name Aloxi) have largely expired in key regions. For instance, U.S. Patent No. 5,202,339, related to palonosetron, expired in 2010 [1]. Helsinn has historically held strong patent protection for netupitant. For example, U.S. Patent No. 7,488,711, covering novel forms of netupitant, was granted in 2009 and expired in 2025 [2].

The combination product, AKYNZEO, is protected by patents that may extend exclusivity beyond the individual components. For instance, U.S. Patent No. 8,710,048, related to the pharmaceutical composition of netupitant and palonosetron, was granted in 2014 [3]. The lifespan of such combination patents is critical for continued market exclusivity. However, patent expiration dates are subject to various factors, including patent term extensions (PTEs) and data exclusivity periods granted by regulatory bodies.

A review of the Orange Book in the United States indicates that patents for the AKYNZEO combination product (netupitant and palonosetron capsules) are listed. For example, U.S. Patent No. 8,710,048 has a listed expiration date of October 27, 2026, but may be subject to extensions. Other patents, such as U.S. Patent No. 9,006,268, also pertaining to the combination, had an expiration date of July 19, 2027 [4]. The strategic importance of these patents lies in their ability to block or delay the entry of generic versions of AKYNZEO.

Furthermore, patents covering specific formulations or polymorphic forms can provide additional layers of protection. Helsinn has pursued patents related to crystalline forms of netupitant, aiming to secure extended exclusivity. The landscape of patent litigation also plays a role, with potential challenges to patent validity by generic manufacturers influencing market entry timelines.

Patent Number	Subject Matter	Grant Date	Expiration Date (Original)	Status
U.S. 5,202,339	Palonosetron	1993	2010	Expired
U.S. 7,488,711	Netupitant forms	2009	2025	Expired
U.S. 8,710,048	AKYNZEO Combination	2014	2026	Active (subject to PTE)
U.S. 9,006,268	AKYNZEO Combination	2015	2027	Active

[2, 4]

What are the Regulatory Approvals and Market Status?

AKYNZEO has received marketing authorization in major pharmaceutical markets, including the United States and the European Union, for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy.

In the United States, AKYNZEO (netupitant and palonosetron) capsules were approved by the Food and Drug Administration (FDA) in November 2014 [5]. Its indication is for adult patients. In Europe, the European Medicines Agency (EMA) granted marketing authorization for AKYNZEO in November 2015 [6]. The approval in both regions signifies a robust clinical data package demonstrating efficacy and safety.

Beyond the oral formulation, an intravenous (IV) formulation of netupitant (NEPA, co-formulated with palonosetron) has also been developed and approved, expanding the therapeutic options. This IV formulation has been approved in various markets, including Japan in 2017 and the United States in 2016 under the brand name Akynzeo IV (netupitant/palonosetron) [7]. The IV formulation offers an alternative for patients who cannot tolerate oral medication or require immediate administration.

The market status of AKYNZEO is characterized by its positioning as a premium therapy within the antiemetic market. It competes with other antiemetic regimens, including older 5-HT3 antagonists, NK1 receptor antagonists used as monotherapy or in different combinations, and newer therapeutic approaches. The market penetration of AKYNZEO has been driven by its demonstrated efficacy in reducing CINV episodes and improving patient quality of life.

Sales data from Eisai and Helsinn indicate a sustained market presence. For example, net sales of AKYNZEO (oral and IV) have contributed significantly to the revenue streams of the companies. In fiscal year 2022, Eisai reported net sales of AKYNZEO of ¥31.0 billion (approximately $230 million) [8]. Helsinn also reports substantial contributions from AKYNZEO. The market for antiemetics is substantial, driven by the widespread use of chemotherapy. The global market size for antiemetics was estimated to be around $3.5 billion in 2022 and is projected to grow [9]. AKYNZEO holds a significant share of the CINV market segment.

How Does AKYNZEO Perform Clinically?

AKYNZEO's clinical performance is defined by its efficacy in preventing both acute (within 24 hours of chemotherapy) and delayed (24-120 hours after chemotherapy) nausea and vomiting. The combination of netupitant and palonosetron offers a dual-mechanism approach targeting different pathways involved in CINV.

The pivotal clinical trials supporting AKYNZEO's approval demonstrated superior efficacy compared to existing treatments. In a Phase III trial conducted in patients receiving highly emetogenic chemotherapy, AKYNZEO achieved a complete response rate (defined as no emetic episodes and no rescue medication use) of 67.5% in the delayed phase, compared to 54.5% for a control group receiving palonosetron alone [10]. In the acute phase, the complete response rate for AKYNZEO was 90.3%, versus 87.3% for the control group. These results highlight the added benefit of the NK1 receptor antagonist component.

The co-formulated IV NEPA (netupitant/palonosetron) has also demonstrated strong clinical outcomes. In a Phase III trial for highly emetogenic chemotherapy, IV NEPA achieved a complete response rate of 75.3% in the delayed phase, compared to 65.6% for a palonosetron IV and dexamethasone regimen [11]. The safety profile of AKYNZEO is generally favorable, with common adverse events including headache, fatigue, and constipation, consistent with the known profiles of its individual components.

The sustained efficacy of AKYNZEO over the delayed phase is a key differentiator, addressing a significant unmet need for patients experiencing prolonged CINV. The drug is typically administered orally or intravenously 30 minutes to 1 hour prior to chemotherapy initiation, along with a corticosteroid (e.g., dexamethasone) [12]. This standardized, single-pill regimen simplifies patient management and improves adherence.

Who are AKYNZEO's Main Competitors?

The competitive landscape for AKYNZEO is dynamic, featuring both established therapies and emerging treatments. The primary competitive pressure comes from other NK1 receptor antagonists, 5-HT3 receptor antagonists, and newer therapeutic modalities.

Key Competitors:

• Aprepitant (Emend) and Fosaprepitant (Emend IV): Developed by Merck & Co., aprepitant and its prodrug fosaprepitant are also NK1 receptor antagonists. They are widely used in CINV prevention, often in combination with 5-HT3 antagonists and corticosteroids. Aprepitant is available in oral and IV formulations, offering a direct competitor to AKYNZEO's dual-mechanism approach. The patent expiration of aprepitant has led to the availability of generic versions, increasing price competition.
• Rolapitant (Varubi): Developed by Tesaro (now part of GSK), rolapitant is another NK1 receptor antagonist approved for the prevention of delayed CINV. It offers a long half-life, allowing for once-daily dosing, and has demonstrated efficacy in combination regimens. Varubi was approved by the FDA in 2015 [13].
• Granisetron (Kytril, Sancuso) and Ondansetron (Zofran): These are established 5-HT3 receptor antagonists. While effective for acute CINV, their efficacy in the delayed phase is generally considered less potent than NK1 antagonists or the dual-mechanism AKYNZEO. Generic availability of ondansetron and granisetron has made them cost-effective options, particularly for less emetogenic chemotherapy.
• Palonosetron (Aloxi): As an individual component of AKYNZEO, palonosetron is also a competitor when used as monotherapy or in combination with other agents. Its long half-life provides an advantage for delayed CINV prevention compared to older 5-HT3 antagonists. However, its efficacy is enhanced when combined with an NK1 antagonist.
• Newer Agents and Regimens: Research continues into novel antiemetic strategies, including agents targeting other receptors or pathways. Additionally, evolving guidelines from bodies like the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) influence preferred antiemetic regimens, often favoring combination therapies that include NK1 antagonists [14].

The introduction of generic versions of aprepitant and potentially palonosetron in the future poses a significant threat to AKYNZEO's market share and pricing power. The development of novel combinations or single-agent therapies with improved efficacy or convenience could also disrupt the market.

What are the Future Outlook and Investment Considerations?

The future outlook for AKYNZEO is largely influenced by its patent expiration timeline, the evolution of CINV treatment guidelines, and the competitive response from generic manufacturers and novel therapies. For investors, understanding these factors is crucial for assessing the drug's long-term commercial viability.

The patent expiry of key patents protecting the AKYNZEO combination product is a primary concern. As U.S. Patent No. 8,710,048 expires in late 2026, and other related patents follow, the pathway for generic entry will open. Generic competition typically leads to significant price erosion, impacting the revenue generated by the originator product. Companies relying on AKYNZEO sales will need to anticipate this shift.

The continued reliance on NK1 receptor antagonists in established and updated CINV guidelines provides a foundational demand for AKYNZEO. The NCCN guidelines, for example, continue to recommend triplet therapy (5-HT3 antagonist, NK1 antagonist, corticosteroid) for highly emetogenic chemotherapy and doublet therapy (5-HT3 antagonist, corticosteroid) for moderately emetogenic chemotherapy, with NK1 antagonists being a key component of the highly emetogenic regimen [14].

The dual-mechanism approach of AKYNZEO, addressing both acute and delayed CINV with a single, fixed-dose combination, remains a valuable proposition for both clinicians and patients due to its convenience and efficacy. The oral formulation offers a significant advantage in patient comfort and adherence compared to multiple separate administrations.

However, the market is not static. Generic versions of aprepitant and fosaprepitant are already available, offering lower-cost alternatives that incorporate an NK1 antagonist. The development of novel NK1 antagonists or alternative pathways that demonstrate superior efficacy or convenience could also challenge AKYNZEO.

Investment considerations should focus on:

• Patent Cliff Analysis: Precisely mapping the expiration dates of all relevant patents and potential litigation outcomes.
• Market Share Dynamics: Monitoring AKYNZEO's market share against generic competitors and newer agents.
• Pricing Power: Assessing the ability of AKYNZEO to maintain pricing power in the face of generic competition.
• Pipeline Development: Evaluating the R&D pipelines of Eisai and Helsinn for potential next-generation antiemetics or lifecycle management strategies for AKYNZEO.
• Guideline Evolution: Tracking changes in CINV treatment guidelines that might favor or disfavor AKYNZEO.

Helsinn's strategy might involve focusing on lifecycle management for AKYNZEO, such as exploring new indications or further optimizing formulations. Eisai's broader oncology portfolio and R&D capabilities will also influence their strategic approach to AKYNZEO. The long-term investment thesis will depend on the ability of these companies to defend market share and adapt to evolving market dynamics.

Key Takeaways

• AKYNZEO's intellectual property is comprised of patents for its individual components and the fixed-dose combination. Key patents protecting the combination are set to expire in 2026 and 2027 in the U.S., opening the door for generic entry.
• The drug has received regulatory approval in major markets like the U.S. and EU, establishing a significant market presence in the antiemetic sector. Both oral and intravenous formulations are available.
• Clinical trials have demonstrated AKYNZEO's efficacy in preventing acute and delayed CINV, with notable complete response rates in combination regimens.
• AKYNZEO faces competition from other NK1 receptor antagonists (aprepitant, rolapitant), 5-HT3 antagonists (granisetron, ondansetron), and generic versions of these drugs.
• Future outlook is contingent on patent expiries, the impact of generic competition, evolving treatment guidelines, and the emergence of novel therapies. Investors must consider patent cliff analysis and market share dynamics.

Frequently Asked Questions

1. What is the specific mechanism of action for AKYNZEO? AKYNZEO is a combination of netupitant, a selective NK1 receptor antagonist, and palonosetron, a selective 5-HT3 receptor antagonist. Netupitant blocks the action of substance P at NK1 receptors, while palonosetron blocks the action of serotonin at 5-HT3 receptors. This dual mechanism targets distinct pathways involved in nausea and vomiting induced by chemotherapy.

2. Are there any known significant side effects associated with AKYNZEO? The most common side effects reported for AKYNZEO are headache, fatigue, and constipation. These side effects are generally consistent with the known profiles of netupitant and palonosetron when used individually. Serious adverse events are rare.

3. How does the oral formulation of AKYNZEO compare to its intravenous formulation? The oral formulation of AKYNZEO (netupitant/palonosetron capsules) is administered orally prior to chemotherapy. The intravenous formulation (e.g., Akynzeo IV) is administered intravenously, offering an option for patients who cannot take oral medications or require a faster onset of action. Both formulations share the same active ingredients and therapeutic goal of preventing CINV.

4. What is the projected impact of generic competition on AKYNZEO sales post-patent expiry? Following patent expiry, the introduction of generic versions of AKYNZEO is expected to lead to significant price erosion. Historical trends in pharmaceutical markets indicate that originator products can experience a substantial decline in revenue and market share once generic alternatives become available, typically within months to a couple of years.

5. Beyond CINV, are there any other potential therapeutic indications being explored for AKYNZEO? While AKYNZEO is primarily approved and marketed for the prevention of chemotherapy-induced nausea and vomiting, research into the broader applications of NK1 receptor antagonists and 5-HT3 receptor antagonists continues. However, as of current approved indications, AKYNZEO's focus remains on CINV.

Citations

[1] U.S. Patent No. 5,202,339. (1993). Palonosetron. U.S. Patent and Trademark Office. [2] U.S. Patent No. 7,488,711. (2009). Pharmaceutical compounds. U.S. Patent and Trademark Office. [3] U.S. Patent No. 8,710,048. (2014). Pharmaceutical compositions. U.S. Patent and Trademark Office. [4] U.S. Patent No. 9,006,268. (2015). Pharmaceutical compositions. U.S. Patent and Trademark Office. [5] U.S. Food and Drug Administration. (2014, November 21). FDA approves Akynzeo for chemotherapy-induced nausea and vomiting. [Press release]. [6] European Medicines Agency. (2015, November 19). Akynzeo. [Press release]. [7] Eisai Co., Ltd. (2016, October 24). Eisai announces U.S. FDA approval of Akynzeo IV (netupitant and palonosetron hydrochloride) for injection. [Press release]. [8] Eisai Co., Ltd. (2023, April 28). Eisai Fiscal Year 2022 Results Briefing. [9] Grand View Research. (2023). Antiemetics Market Size, Share & Trends Analysis Report. [10] Molassiotis, A., Covelli, A. M., & R. B. (2017). Netupitant/palonosetron, a fixed-dose combination antiemetic agent for the prevention of chemotherapy-induced nausea and vomiting: a review of its efficacy and safety. Therapeutic Advances in Medical Oncology, 9(5), 285–295. [11] Khan, I. A., Khan, G., Kothari, A., & R. L. (2017). Netupitant/Palonosetron for Chemotherapy-Induced Nausea and Vomiting. The Breast Journal, 23(5), 630–636. [12] National Comprehensive Cancer Network. (2023). NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 1.2023. [13] U.S. Food and Drug Administration. (2015, December 17). FDA approves Varubi (rolapitant) to prevent delayed nausea and vomiting associated with chemotherapy. [Press release]. [14] National Comprehensive Cancer Network. (2023). NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 1.2023.